SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: AZD2014|DRUG: AZD4547|DRUG: AZD5363|DRUG: AZD8931|DRUG: Selumetinib|DRUG: Vandetanib|DRUG: Bicalutamide|DRUG: Olaparib|DRUG: Anthracyclines|DRUG: Taxanes|DRUG: cyclophosphamide|DRUG: DNA intercalators|DRUG: Methotrexate|DRUG: vinca alkaloids|DRUG: Platinum based chemotherapies|DRUG: Bevacizumab|DRUG: Mitomycin C|DRUG: Eribulin|DRUG: MEDI4736
Sponsor: UNICANCER
Collaborators: Fondation ARC|AstraZeneca